X0407 4 2023-04-19 0 0001831097 agilon health, inc. AGL 0001855973 Desai Veeral C/O AGILON HEALTH, INC. 6210 E HWY 290, SUITE 450 AUSTIN TX 78723 0 1 0 0 Chief Strategy & Dev. Officer 1 Common Stock 2023-04-19 4 M 0 5000 3.00 A 304585 D Common Stock 2023-04-19 4 S 0 4545 26.8157 D 300040 D Common Stock 2023-04-19 4 S 0 455 27.8382 D 299585 D Common Stock 2023-04-20 4 M 0 500 3.00 A 300085 D Common Stock 2023-04-20 4 S 0 500 26.148 D 299585 D Options (Rights to Buy) 3.00 2023-04-19 4 M 0 5000 0.00 D 2027-04-27 Common Stock 5000 1515000 D Options (Rights to Buy) 3.00 2023-04-20 4 M 0 500 0.00 D 2027-04-27 Common Stock 500 1514500 D Includes restricted stock units. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan effective September 14, 2022. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $26.56 to $27.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $27.73 to $27.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $26.08 to $26.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. These options were granted on April 27, 2017 and vested on September 14, 2021. /s/ Steve Meetre, as Attorney-in-Fact 2023-04-21